|
|
Article: Artes Medical Broadens Product Portfolio Through Exclusive U.S. Sales and Marketing Agreement for Elevess, a New FDA-Approved Hyaluronic Acid-Based Dermal Filler.
- Article from:
- Business Wire
- Article date:
- July 8, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Artes Medical, Inc. (Nasdaq:ARTE), a medical aesthetics company, today announced that it has entered into an exclusive U.S. sales and marketing agreement with Anika Therapeutics Inc. (Nasdaq:ANIK) for Elevess, Anika's proprietary FDA-approved hyaluronic acid (HA) based temporary dermal filler for the correction of facial wrinkles and folds.
Through this agreement, Artes Medical's dedicated sales force will market and sell Elevess, the first FDA-approved HA dermal filler for the temporary correction of facial wrinkles that is formulated with an anesthetic for patient comfort, as well as the company's flagship product, ArteFill, the first and only ...